✦ LIBER ✦

The clinical evaluation of the Endeavor zotarolimus-eluting coronary stent in Japanese patients with de novo native coronary artery lesions: primary results and 3-year follow-up of the Endeavor Japan study

✍ Scribed by Shigeru Saito; Ross Prpic; Jeffery J. Popma; John Alexander; Mitchell W. Krucoff

Book ID: 113516168
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 150 KB
Volume: 12
Category: Article
ISSN: 1553-8389
DOI: 10.1016/j.carrev.2010.12.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

FIVE YEAR CLINICAL RESULTS FROM ENDEAVOR

FIVE YEAR CLINICAL RESULTS FROM ENDEAVOR III: A RANDOMIZED COMPARISON OF THE ZOTAROLIMUS-ELUTING VERSUS SIROLIMUS-ELUTING STENTS IN DE NOVO NATIVE CORONARY LESIONS

✍ Kandzari, David E.; Mauri, Laura; Popma, Jeffrey; Turco, Mark A.; O'Shaunessy, C 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Improved Late Clinical Safety With Zotar

Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in Patients With De Novo Coronary Lesions: 3-Year Follow-Up From the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) Trial

✍ Martin B. Leon; Eugenia Nikolsky; Donald E. Cutlip; Laura Mauri; Henry Liberman; 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 557 KB

Late-Term Clinical Outcomes With Zotarol

Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)

✍ David E. Kandzari; Laura Mauri; Jeffrey J. Popma; Mark A. Turco; Paul A. Gurbel; 📂 Article 📅 2011 🏛 American College of Cardiology 🌐 English ⚖ 704 KB

TCT-404: Late Safety and Efficacy of a Z

TCT-404: Late Safety and Efficacy of a Zotarolimus-Eluting Stent Compared with a Paclitaxel-Eluting Stent in Patients with De Novo Coronary Lesions: Three-Year Follow-up from the ENDEAVOR IV Trial

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 228 KB

The Relation Between Clinical Features,

The Relation Between Clinical Features, Angiographic Findings, and the Target Lesion Revascularization Rate in Patients Receiving the Endeavor Zotarolimus-Eluting Stent for Treatment of Native Coronary Artery Disease: An Analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III

✍ Rajendra H. Mehta; Martin B. Leon; Michael H. Sketch Jr 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 398 KB

SPIRIT II STUDY: EVALUATION OF THE XIENC

SPIRIT II STUDY: EVALUATION OF THE XIENCE V EVEROLIMUS ELUTING CORONARY STENT IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS: 5-YEAR RESULTS

✍ Onuma, Yoshinobu; Serruys, Patrick W. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 118 KB